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Available online 05 July 2017We critically assess the proposal that succinate-fuelled reverse electron ﬂow (REF) drives mitochondrial matrix
superoxide production fromComplex I early in reperfusion, thus acting as a keymediator of ischemia/reperfusion
(IR) injury. Real-time surface ﬂuorescence measurements of NAD(P)H and ﬂavoprotein redox state suggest that
conditions are unfavourable for REF during early reperfusion. Furthermore, rapid loss of succinate accumulated
during ischemia can be explained by its efﬂux rather than oxidation. Moreover, succinate accumulation during
ischemia is not attenuated by ischemic preconditioning (IP) despite powerful cardioprotection. In addition,mea-
surement of intracellular reactive oxygen species (ROS) during reperfusion using surface ﬂuorescence andmito-
chondrial aconitase activity detected major increases in ROS only after mitochondrial permeability transition
pore (mPTP) openingwas ﬁrst detected.We conclude thatmPTP opening is probably triggered initially by factors
other than ROS, including increased mitochondrial [Ca2+]. However, IP only attenuates [Ca2+] increases later in
reperfusion, again after initial mPTP opening, implying that IP regulatesmPTP opening through additional mech-
anisms. One such ismitochondria-bound hexokinase 2 (HK2)which dissociates frommitochondria during ische-
mia in control hearts but not those subject to IP. Indeed, there is a strong correlation between the extent of HK2
loss frommitochondria during ischemia and infarct size on subsequent reperfusion.Mechanisms linkingHK2dis-
sociation tomPTP sensitisation remain to be fully established but several related processes have been implicated
including VDAC1 oligomerisation, the stability of contact sites between the inner and outer membranes, cristae
morphology, Bcl-2 family members and mitochondrial ﬁssion proteins such as Drp1.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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It is now widely accepted that the irreversible injury of the heart
which occurs during reperfusion after a prolonged period of ischemia
is mediated, at least in part, by opening of themitochondrial permeabil-
ity transition pore (mPTP) [1,2]. This starts after about 2min of reperfu-
sion [3,4] and coincideswith the intracellular pH (pHi) returning to pre-
ischemic values from the low values (b6.5) that are reached after
prolonged ischemia and which inhibit mPTP opening [5]. Opening of
the mPTP not only compromises cellular bioenergetics, thus impairing
the re-establishment of pre-ischemic levels of ions such as calcium,
but also causes mitochondria to release reactive oxygen species (ROS)
[6,7]. The resulting increases in ROS and [Ca2+] induce further mPTP
opening and bioenergetic compromise leading to a spreading wave of
necrotic cell death that produces the infarct [1,8]. Pharmacological inhi-
bition ofmPTP opening by cyclosporin A (CsA) [9], sanglifehrin A [10] or
cinnamic anilides [11] can protect hearts from ischemia/reperfusion
(IR) injury as can ischemic preconditioning (IP) and post-conditioning,
both of which also inhibit mPTP opening [1,8].
Although the precise molecular composition of the mPTP remains
uncertain [2,12,13], it is well established that increases in matrix
[Ca2+] trigger mPTP opening and that its sensitivity to [Ca2+] is greatly
enhanced by oxidative stress, elevated phosphate and decreasedmatrix
adenine nucleotides [1]. These are all conditions associated with IR. In-
deed, the combination of increased matrix [Ca2+] with oxidative stress
is now widely regarded as the main trigger for mPTP opening during
early reperfusion [1,2]. Oxidative stresswithin thematrix is an especial-
ly attractive candidate since this overcomes the powerful inhibitory ef-
fect of adenine nucleotides on mPTP opening leading to a profound
increase in Ca2+ sensitivity [14]. Furthermore, several studies, including
our own, have shown oxidative stress to increase during reperfusion
and to be greatly attenuated by a variety of protocols that induce
cardioprotection including IP [15,16], temperature preconditioning
(TP) [17], urocortin [18], apomorphine [19], ischemic post-conditioning
[20] and sequential exposure to isoproterenol and adenosine [21]. How-
ever, it is alsowell established that increased superoxide production can
occur as a consequence ofmPTP opening [6,7], caused in part by the loss
of cytochrome c and NADPH from the mitochondria, both of which are
important for ROS scavenging [6,22]. Thus, it is important to establish
whether increased levels of ROS precedemPTP opening during early re-
perfusion or occur later as a consequence of mPTP opening.
Recently, Murphy, Krieg and colleagues have presented extensive
data to implicate superoxide production from the matrix surface of
Complex I early in reperfusion as a key player in IR injury [23–26].
They propose that this superoxide production occurs because succinate
accumulates in the heart during ischemia and is rapidly oxidised by re-
verse electron ﬂow (REF) at the start of reperfusion. This induces a high-
ly reduced state of the ubiquinone binding site on the matrix face of
Complex I that drives superoxide production [23]. Here we critically as-
sess the role of succinate-mediated superoxide production from Com-
plex I in IR injury and conclude that it is unlikely to be the primary
trigger of mPTP opening in the early phase of reperfusion and which is
modulated by IP. Rather, we suggest that it is elevated [Ca2+] thatinitiatesmPTP opens on reperfusion and that IP attenuates other factors
that sensitise the mPTP to [Ca2+], including the well-established disso-
ciation of hexokinase 2 (HK2) from its mitochondrial binding site that
occurs during ischemia [27–29]. However, substantial ROS production
does occur later in reperfusion as a consequence of initial mPTP open-
ing, and this leads to further pore opening and an expanding area of ne-
crotic cell death that forms the infarct. Cardioprotective protocols such
as IP prevent HK2 loss from mitochondria during ischemia and so pre-
vent both phases of mPTP opening.
2. Does mitochondrial superoxide production precede mPTP open-
ing during reperfusion?
2.1. ROS measurements
The American Heart Association has recently published a “Scientiﬁc
Statement” on the measurement of ROS species which provides a com-
prehensive review of the available methods, their limitations and what
combined approaches are recommended for particular situations [30].
As this article makes abundantly clear, measurement of ROS species is
not straight forward, and although many different methods can be
used, each approach is fraught with potential pitfalls for the unwary.
Some of these issues are noted in the discussion below, but the main
focus of this section is to provide a critical review of the data relating
the time course of ROS formation in the ischemic/reperfused heart to
the time course of mPTP opening.
2.1.1. Studies using isolated cardiac myocytes
Studies using isolated adult cardiac myocytes subject to simulated
ischemia and reperfusion have provided evidence that ROS production
precedes mPTP opening and cell death [23,31–33]. However, to simu-
late ischemia, these studies employed bicarbonate-free media and an-
oxia together with low pH, with or without the addition of L-lactate,
followed by return to normal medium (still bicarbonate free) to mimic
reperfusion. In such studies, the cardiomyocytes are usually quiescent
or at best stimulated to beat at very low frequency and it is questionable
whether these conditions adequately reproduce those occurring in the
intact ischemic/reperfused heart. In the beating perfused heart there
will be a much higher metabolic turnover and Ca2+ cycling rates than
in isolated cardiac myocytes with the consequence that mitochondria
will be in a different redox and bioenergetic state. This may reduce
both their ability to accumulate Ca2+ and produce ROS. Furthermore,
the concentration of myocytes in the heart, and their complex interac-
tions with each other and endothelial cells, cannot be adequately
reproduced when using isolated myocytes for ﬂuorescencemicroscopy.
Nor can the build-up and subsequent washout of metabolites that oc-
curs in the ischemic reperfused heart, while the absence of bicarbonate
will disrupt normal pH regulatory mechanisms. In addition, the studies
with cardiac myocytes [32,33] generally used much longer periods of
simulated ischemia than are routinely employed in studies with the
perfused heart and thus are difﬁcult to compare with data obtained
using the ischemic/reperfused heart. A more recent study using
dihydroethidium (DHE) as the superoxide-sensitive dye has measured
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concerns have been expressed over the use of DHE as a ROS probe,
both in terms of whether the ﬂuorescent species monitored really de-
tects superoxide [34] and its sensitivity to changes in mitochondrial
membrane potential [35] as discussed further below (Section 2.1.2).
For these reasons, we suggest that any conclusions drawn from isolated
cardiomyocyte experiments must be treated with caution, especially
where they differ those obtained using the perfused heart.
2.1.2. Studies using the perfused heart
Measurements of ROS production/oxidative stress have been made
in the ischemic/reperfused heart, but the majority of these studies
lacked the time resolution to establish whether ROS increases before
or after mPTP opening. Thus determinations of protein carbonylation
[15–17,19–21,24], protein thiolation [36], lipid peroxidation [37–39]
and aconitase activity [23] have all clearly demonstrated that oxidative
stress does occur during reperfusion, but do not provide information on
whether there is a signiﬁcant increase in ROS within the ﬁrst minute or
two, prior to initial mPTP opening. The same is true for the measure-
ment of mitochondrial superoxide using themitochondrial targeted hy-
drogen peroxide probe, mito B, assayed using mass spectrometry of
freeze clamped tissue. Here the earliest time point reported was at
15 min [23,24]. More rapid detection of increased ROS production has
been obtained using hearts perfused with the electron paramagnetic
resonance (EPR) free radical probe 5,5-dimethyl-1-pyroline-n-oxide
(DMPO) where peak concentrations of radical formation were detected
after 10–20 s of reperfusion followed by a gradual decline over the next
1–2 min [40]. It was demonstrated that these radicals were derived
from superoxide since reperfusion in the presence of enzymatically ac-
tive recombinant human superoxide dismutase (SOD) markedly re-
duced the formation of the relevant EPR signals while inactive SOD
had no effect. However, the effect of SOD implies that the location of
the superoxide detected was extracellular since otherwise it would
not be attenuated by membrane-impermeable SOD. In a separate set
of experiments in which hearts were rapidly freeze-clamped and en-
dogenous radicals measured using EPR, a similar time course of radical
formation was detected [41] which is more likely to reﬂect intracellular
superoxide formation over this time period. Indeed, measurements of
the reversible glutathionylation of glyceraldehyde 3 phosphate dehy-
drogenase did detect an increase within 1 min of reperfusion after
30 min ischemia [42]. The luminescent probe lucigenin (N,N′-dimeth-
yl-9,9′-biacridinium dinitrate) also detected increases in superoxide
within a minute or so of reperfusion, but these only reached a peak at
about 5 min [35] which is after mPTP opening [3,4]. It has been sug-
gested that the positive charge on this probemay lead to its preferential
uptake and retention by mitochondria and some evidence for this has
been presented [35]. However, others have argued that its permeability
into cells is an issue and that a signiﬁcant proportion of the signal may
represent extracellular superoxide production [30].
Surface ﬂuorescence of the Langendorff-perfused heart has also
been used to monitor ROS production in real time during IR. There are
signiﬁcant problems associatedwith this approach includingmotion ar-
tefacts, internal ﬁltering of the incident and emitted light by cyto-
chromes, ﬂavoproteins and myoglobin, and autoﬂuorescence by
NAD(P)H and ﬂavoproteins. We have discussed these issues more
fully elsewhere [7]. Of particular concern is that both autoﬂuorescence
and internal ﬁltering change dramatically in the transition between
normoxia and ischemia as myoglobin becomes deoxygenated and the
cytochromes and ﬂavoproteins become reduced. Although these effects
rapidly reverse on reperfusion, it is only when this process is complete
that reliable conclusions can be drawn from the crude ﬂuorescent sig-
nals. This is a particular problem for dihydroethidium (DHE) which
has been employed as a superoxide-speciﬁc ﬂuorescent probe in several
perfused heart studies [35,43–50]. DHE itself is not ﬂuorescent but once
oxidised by superoxide to 2-hydoxyethidium it ﬂuoresces at N600 nm
when excited at ~535 nm. Unfortunately, this makes the probeespecially sensitive to changes in myoglobin oxygenation and the
redox state of cytochromes. Indeed, such effects probably account for
the very rapid increase and decrease in ﬂuorescence seen upon ische-
mia and reperfusion respectively [43]. This makes it very difﬁcult to as-
sess whether rapid changes in ROS are occurring early in reperfusion.
Additional concerns have been expressed over the use of DHE as a
ROS probe, both in terms of whether the ﬂuorescent species monitored
reﬂects superoxide [30,34] and its sensitivity to changes in mitochon-
drial membrane potential [35]. Nevertheless, in the perfused heart
slower increases in signal are seen after about 3–4 min of reperfusion
that are prevented by IP [43] and would seem likely to reﬂect changes
in ROS as revealed by our own studieswith alternative probes described
below.
We have recently published extensive data from experiments in
which we continuously measured ROS production in the beating heart
subject to IR using a bespoke surface ﬂuorescence apparatus to monitor
the surface ﬂuorescence atmultiplewavelengthswith high time resolu-
tion [7]. Simultaneous measurements were made of hemodynamic
function together with surface reﬂectances at both the excitation and
emission wavelengths of all probes used. The latter measurements
allowed monitoring of potential artefacts caused by changes in surface
geometry (such as occurs during ischemic contracture), although in
the optical conﬁguration employed it was found that such artefacts
were minimal. We also determined the ﬂuorescence emission spectra
for each dye loadedwithin the heart at various times of ischemia and re-
perfusion to assess the effects of internal ﬁltering caused bymyoglobin,
cytochromes and ﬂavoproteins. These measurements revealed that all
ﬂuorescent probes were likely to be subject to interference by internal
ﬁltering during the ﬁrst 10–15 s of ischemia and reperfusion, although
the use of the ROS-insensitive dye, calcein, monitored under the same
conditions, allowed some estimate of these effects to bemade.Measure-
ments after 10–15 s of reperfusion were not subject to major
artefacts and thus provided robust data. Three different ROS probes
were employed to detect changes during reperfusion in control
hearts and those subject to IP. These were 5-carboxy-2′,7′-
dichlorodihydroﬂuorescein diacetate (5-cH2DCFDA), a generic ROS
probe whose exact speciﬁcity is uncertain [51], and two caged boronate
probes that are speciﬁc for hydrogen peroxide: Peroxy-Orange 1 (PO1)
which measures primarily cytosolic hydrogen peroxide and Mitochon-
dria Peroxy-Yellow1 (MitoPY1) that is targeted tomitochondria. In par-
allel we measured aconitase activity in mitochondria isolated after 90 s
reperfusion as an additional indicator of mitochondrial ROS. As shown
in Fig. 1, both 5-cH2DCFDA and PO1 revealed a similar pattern of ROS
production; in both cases no signiﬁcant increase in ROS was detected
until after about 1.5–2 min of reperfusion. By measuring the loss of
calcein entrapped within the mitochondria we conﬁrmed that this
was after mPTP opening had occurred [7]. The progressive increase in
ROS observed after about 2 min of reperfusion was attenuated by both
IP and CsA which also reduced infarct size and inhibited mPTP opening
as detected previously usingmitochondrial 2-deoxyglucose entrapment
[52] andmore recently with calcein entrapment [7]. Thus our data with
both 5-cH2DCFDA and PO1 suggest that these probes only detected ROS
production after initial mPTP opening. We were also unable to detect
any increase in mitochondrial ROS at 90 s of reperfusion using either
the mitochondria-targeted hydrogen peroxide probe MitoPY1 or
aconitase activitymeasurements [7]. As noted before, both aconitase ac-
tivity and the superoxide probe mitoB did detect an increase in mito-
chondrial ROS after 15 min reperfusion [23], but again this is after
mPTP opening and thus may well be a consequence of mPTP opening
rather than a primary cause.
Overall, we suggest that ROS probes such as DHE, DMPO and
lucigenin that report increases in ROS levels within the ﬁrst minute of
reperfusion are probably not detecting ROS within the mitochondria.
As such they provide no strong evidence for IP-sensitive increases in su-
peroxide within the mitochondrial matrix early in reperfusion that
could stimulatemPTP opening. It maywell be that some of these probes
Fig. 1. Time course of ROS production measured using surface ﬂuorescence in the
Langendorff-perfused heart subject to ischemia and reperfusion. Both control and IP
hearts were pre-loaded with either 5-cH2DCFDA as its di-(acetoxymethyl ester) or PO1
and then subject to 30 min index ischemia followed by reperfusion for the time shown.
Data are expressed as means ± SEM (error bars) for 6 (5-cH2DCFDA) or 9–11 (PO1)
separate heart perfusions and are taken from [7] where further details may be found.
Signiﬁcant differences between control and IP hearts, calculated by unpaired t-test, are
shown by horizontal lines (*p b 0.05; **p b 0.01).
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by enzymes such as NADPH oxidase, uncoupled nitric oxide synthase,
monoamine oxidase and xanthine oxidase [53–56]. Cytosolic superox-
ide is likely to be rapidly scavenged by SOD, glutathione peroxidase
and glutathione reductase [57,58] before it can enter the mitochondrial
matrix as suggested by the rapid increase in glutathionylated proteins
such as glyceraldehyde 3 phosphate dehydrogenase [42].
2.2. Effects of ROS scavengers
If an increase in mitochondrial superoxide production in the matrix
is a key trigger for mPTP opening early in reperfusion, then
intramitochondrial ROS scavengers (reviewed in [59]) should be
cardioprotective. Mitochondria-targeted Szeto-Schiller peptides (also
known as Bendavia) do reduce ROS production by isolated mitochon-
dria [60] and are mildly cardioprotective in some models of IR injury
[58,60–64]. However, exactly how these agents work is unclear since
they do not act as scavengers of deﬁned reactive oxygen species pro-
duced in vitro [60] and thus are not acting as true ROS scavengers. Themitochondria-targeted ubiquinone derivative MitoQ is an established
superoxide scavenger [65] and there is a single report of its ability to
protect hearts from IR injury [66]. However, these data were obtained
in a whole animal model in which rats were treated for 14 days with
MitoQ in their drinking water before induction of myocardial ischemia.
Thus, it cannot be ruled out that cardioprotectionwas secondary to lon-
ger term effects of MitoQ and not directly viamitochondrial ROS scav-
enging in the heart itself. Indeed, studies from this laboratory failed to
demonstrate cardioprotection by MitoQ in the Langendorff-perfused
heart [67]. Furthermore, in the many studies that have investigated
the potential cardioprotective effects of a range of ROS scavengers dur-
ing reperfusion,most have proved relatively ineffective at preventing IR
injury in both the clinical setting and in vivo or ex vivo animal models of
IR (reviewed in [68,69]). Nevertheless, transgenic mice overexpressing
either catalase or glutathione peroxidase are somewhat resistant to IR
injury [70,71].
The lack of effect of some ROS scavengersmay be partially explained
if ROS also play a role in cardioprotective signalling pathways as has
been suggested [69,72]. However, even in those cases where ROS scav-
engers do provide cardioprotection, it does not follow that this is the re-
sult of an inhibition of the initial phase ofmPTP opening. Rather, it could
be because ofmore efﬁcient scavenging of the ROS produced after initial
mPTP opening and thus the prevention of an escalating cascade of fur-
ther ROS-sensitised mPTP opening and injury. This may also be true
for the cardioprotection offered by pyruvate [73–75] and the anaesthet-
ic propofol [76,77], both of which are ROS scavengers. Pyruvate exerts
especially powerful cardioprotection, but this is thought to be because
it not only acts as a ROS scavenger but also maintains a more acid pH
during ischemia and reperfusion [74,75].
3. Assessing the evidence that succinate-driven reverse electronﬂow
mediates superoxide production at Complex I during reperfusion
Complex I can generate large amounts of superoxide in thematrix by
twomechanisms: ﬁrst, at the ﬂavinmononucleotide (FMN) sitewhen it
is in a highly reduced state such as under conditions of high protonmo-
tive force (pmf) and low rates of ATP synthesis (State 4); second, at an-
other less well deﬁned site when electrons are donated to the
ubiquinone (CoQ) pool by REF. The latter occurs under conditions of
very high pmf, especially when the pH gradient component is large,
and is caused by the highly reduced state of the CoQ pool forcing elec-
trons back from CoQH2 into Complex I, thus reducing NAD+ to NADH
at the FMN site [78,79]. Since the proportion of the FMN in the fully re-
duced state is set by the NADH/NAD+ ratio, the formermechanismpro-
duces more ROS in the presence of rotenone whereas the latter
mechanism is blocked by rotenone. Importantly, superoxide production
by eithermechanismwill be associatedwith a highmatrix NADH/NAD+
ratio and this can be measured in the intact heart using surface ﬂuores-
cence as can the redox state of ﬂavoproteins which usually follows that
of the NADH/NAD+ ratio [80,81].We havemonitored the rapid changes
in both the NADH/NAD+ and ﬂavoprotein redox state as the heart is re-
perfused following ischemia using real time surface ﬂuorescence and
our data do not provide any support for a role of Complex I in superox-
ide production in the early phase of reperfusion [7].
3.1. Time course of Complex I oxidation
At the onset of ischemia, both NAD(P)H and ﬂavoproteins rapidly
become totally reduced as all oxygen is consumed, and they stay re-
duced until reperfusion is commenced when they rapidly re-oxidise as
illustrated in Fig. 2.
In control and IP hearts re-oxidation of the ﬂavoproteins was 50%
complete within 5 and 15 s respectively and that of NAD(P)H at about
15 and 25 s respectively. The rapid re-oxidation is not unexpected
since during ischemia ATP and creatine phosphate (CrP) are almost to-
tally exhausted and are rapidly regenerated over theﬁrst few seconds of
Fig. 2. Time course of changes in ﬂavoprotein and NAD(P)H surface ﬂuorescence in the
Langendorff-perfused heart subject to ischemia and reperfusion. Surface ﬂuorescence
data (normalised as % of values at the end of ischemia) are only shown for the start of
ischemia (−30 min) and reperfusion (0 min). Data are taken from [7] where further
details may be found, and are presented as means ± SEM (error bars) of 7 control and
IP hearts. Signiﬁcant differences between control and IP hearts calculated by unpaired t-
test are shown by horizontal lines (*p b 0.05; **p b 0.02, ***p b 0.01).
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reperfusion is fast [7], consistent with the rapid oxidation of NADH re-
quired to fuel the increased rates of oxidative phosphorylation. Howev-
er, several features of these data argue against signiﬁcant superoxide
production early in reperfusion. First, the highly reduced state of Com-
plex I required for superoxide production is not maintained for more
than a few seconds. Second, the pmf is unlikely to reach the high values
associated with superoxide formation because of the rapid ﬂow of pro-
tons back into the matrix through the F1Fo ATPase required for ATP re-
synthesis. Third, the rate of re-oxidation of both ﬂavoproteins and
NAD(P)H is slower in IP hearts than control hearts. This does not readily
ﬁt with the proposal that IP reduces superoxide production from Com-
plex I during early reperfusion as would be expected if superoxide is
the key initial trigger for mPTP opening. This slower re-oxidation in IP
hearts, and indeed the slower reduction during the onset of ischemia
(Fig. 2), could reﬂect IP-mediated S-nitrosation of ND3 Cys39 and possi-
bly other Complex I cysteines which inhibit its activity [24,83–86]. An-
other possible explanation would be that IP enhances inhibition of the
mitochondrial ATP synthase by its inhibitor IF1 during ischemia, as
has been observed in some studies (see [87]). This might lead to slower
activation of oxidative phosphorylation and respiration during the ﬁrst
seconds of reperfusion. However, neither explanation would readily ac-
count for a reduction in matrix superoxide production by IP early in
reperfusion.3.2. Succinate measurements
Chouchani et al. [23] conﬁrmed earlier observations [88,89] that suc-
cinate concentrations increase several-fold in ischemic hearts and rap-
idly decrease again on reperfusion. They proposed that this loss of
succinate early in reperfusion reﬂects its oxidation by REF that drives
ROS production at Complex I. As shown in Fig. 3A, we were able to con-
ﬁrm that tissue succinate levels increasemany-fold following 30min is-
chemia of Langendorff-perfused rat hearts, but importantly we found
that a similar accumulation of succinate occurs in IP hearts during ische-
mia [7]. Since IP hearts exhibit less oxidative stress and mPTP opening
after IR than control hearts [7,15,16,52,90,91], this is not what might
be anticipated if succinate oxidation early in reperfusion drives REF
and consequent ROS formation at Complex I. It should also be noted
that a study published nearly twenty years ago [92] demonstrated
that perfusion of hearts with succinate protected them from IR injury
rather than exacerbating injury as might be predicted if succinate
plays an important role in early ROS formation. Furthermore, treatment
of hearts with fumarate is also cardioprotective [93,94] as is genetic
knockdown of fumarate hydratase that causes fumarate accumulation
of the heart [95], and both conditions are associatedwith increased suc-
cinate levels. In ischemia, fumarate and thus succinate are formed dur-
ing the catabolism of aspartate and glutamate and this pathway can
produce some ATP via succinate thiokinase mediated substrate level
phosphorylation. The reduction of fumarate to succinate, mediated via
NADH oxidation through Complex 1, ubiquinone and Complex 2 may
also help maintain the mitochondrial pmf during ischemia. These two
effects are probably responsible for some of the cardioprotection [93–
96]. Fumarate may exert an additional longer term effect through stabi-
lization of the transcriptional regulator Nrf2, perhaps involving
succination of its bindingpartner Keap1, that enhances the transcription
of protective antioxidant genes [95].
It should also be noted that the decrease in succinate observed dur-
ing early reperfusion [23] was shown previously to be associated with
its rapid efﬂux from the heart within 1–2 min of reperfusion [88] and
thereforemight not reﬂect its rapid oxidation as proposed by Chouchani
et al. [23]. It is likely that the proton-linked monocarboxylate carrier,
MCT1, which is highly expressed in the heart [97], facilitates this efﬂux
of succinate since the intracellular pH drops to b6.5 in the ischemic
heart [98] and this will convert N10% of succinate (pKa2 = 5.64) to its
monocarboxylate form. It is known that short-chain substituted
monocarboxylates are good substrates for MCT1 [99], andwe have con-
ﬁrmed this to be the case for themonocarboxylate form of succinate by
studying its uptake into Xenopus laevis oocytes expressing MCT1 as
shown in Fig. 4. Signiﬁcant proton-linked succinate transport was ob-
served at pH 6.0, where 30% of succinate is in its monocarboxylate
form, and this was blocked by AR-C155858, a speciﬁc and potent
MCT1 inhibitor [100], whereas no detectable transport was observed
at pH 7.4 where b2% of succinate is present in its monocarboxylate
form.
3.3. Cardioprotective effects of succinate dehydrogenase inhibition
Additional evidence provided by Chouchani et al. to support the im-
portance of succinate oxidation for ROS production in early reperfusion
was the demonstration that inhibition of succinate dehydrogenase
(SDH) by malonate (generated from membrane-permeable dimethyl
malonate – DMM) reduced ROS production in both isolated
cardiomyocytes and hearts subject to IR [23]. In cardiomyocytes sub-
jected to simulated IR the authors showed that DMM caused a signiﬁ-
cant decrease in ROS after 2 min “reperfusion”. However, they
employed DHE as a ROS probe, which, as discussed earlier, is now
recognised to be unreliable [30,34,35]. Moreover, as noted above, simu-
lated IR in cardiomyocytes does not accurately reproduce the situation
in the whole heart subject to IR. In an in vivomouse model of reperfu-
sion, Chouchani et al. showed that DMM decreased infarct size which
Fig. 3. IP does not attenuate succinate accumulation in ischemia while dimethyl malonate impairs the hemodynamic performance of the Langendorff-perfused heart. Panel A shows the
succinate content (nmol permgdryweight;mean±SEM, n=6)of freeze clamped control (CI) and IP (IPI) hearts following 30min global ischemia; values innormoxic heartswere below
our limit of detection (b0.5 nmol per mg). Data are taken from [7]. Panel B shows that the Rate Pressure Product (RPP) of normoxic Langendorff-perfused rat hearts was decreased by the
presence of increasing concentrations of dimethylmalonate (DMM). Data are expressed as a percentage of values in the absence of DMM (29,900± 2800mmHg*beat/min) and are given
as means ± SEM (error bars) of 7 hearts. Statistical signiﬁcance was determined by paired Student's t-test (*p b 0.01).
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diazoxide [103–105,106,107] to inhibit succinate dehydrogenase. Al-
though the authors used both mitoB and aconitase activity to show
that DMM reduced matrix superoxide levels, these measurements
were made after 15 min of reperfusion [23]. Thus, they may well reﬂect
events occurring after mPTP opening and be secondary to
cardioprotection mediated by DMM through other mechanisms. One
such mechanism would be inhibition of ﬂux through the citric acid
cycle which utilises SDH as an essential component. This would lead
to an impairment of both fatty acid and carbohydrate oxidation which
might compromise the energy status of the heart. Indeed, as discussed
more fully below, cardioprotection can be induced by a range of other
agents and protocols that compromise the energy status of the heart, in-
cluding a range of respiratory chain inhibitors [108], uncouplers [109]
and transient ischemia on reperfusion (post-conditioning) [110]. Fur-
thermore, as shown in Fig. 3B, we have demonstrated that in the
Langendorff-perfused heart, treatmentwith DMM, at similar concentra-
tions to those employed by Chouchani et al. [23], does lead to a progres-
sive reduction in the rate pressure product (RPP) as the DMMFig. 4. Succinate is transported by MCT1 as the monocarboxylate anion. MCT1 was expressed i
using the pH-sensitive ﬂuorescent dye BCECF as described previously [100]. Panel A shows tha
MCT1 at both pH 7.4 and 6.0 but not control oocytes. By contrast, 30 mmol/L succinate (S)
transport as a monocarboxylate (i.e. in the monoprotonated form). Panel B shows that transp
1 μmol/L AR-C155858, a speciﬁc MCT1 inhibitor [100].concentration increased. This is entirely consistent with DMMmediat-
ing its cardioprotective effects through bioenergetic compromise.
3.4. Cardioprotective effects of Complex I inhibitors
Several studies have demonstrated that inhibiting Complex I during
ischemia can reduce ROS formation and IR injury. This is the case for ro-
tenone [111], amobarbital [108,112–114], metformin [115–118] and
most recently by S-nitrosation of ND3onComplex Imediated by themi-
tochondrial-targeted mitoSNO [24,119]. It has been argued by Murphy,
Kreig and colleagues that the cardioprotective effect of Complex I inhi-
bition reﬂects inhibition of ROS production at Complex I [25,26]. How-
ever, a range of other agents and protocols that compromise the
energy status of the heart through diverse mechanisms have been
shown to be cardioprotective. These include uncouplers of oxidative
phosphorylation [109,120], F1Fo ATP synthase inhibitors such as
oligomycin and aurovertin [121], and the adenine nucleotide
translocase (ANT) inhibitors atractyloside and bongkrekic acid [104–
107,122,123]. In addition, transient ischemia on reperfusion (knownn Xenopus laevis oocytes proton-linked monocarboxylate transport measured in real time
t 30 mmol/L L-lactate (L) is transported into and out of Xenopus laevis oocytes expressing
is only transported after the external pH has been decreased to 6.0 consistent with its
ort of both succinate and L-lactate at pH 6.0 is blocked by prior exposure of the oocyte to
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[110,124] and is associated with impaired respiration and slower resto-
ration of intracellular pH during reperfusion. In all these cases the heart
is forced to generate ATP by glycolysis producing lactic acid which will
result in a low intracellular pH being maintained for longer during the
early stages of reperfusion. Opening of the mPTP is inhibited at pH
values below 7 [5] andmaintaining themPTP in a closed state for longer
during early reperfusion may allow restoration of ionic homeostasis,
preventing calcium overload and thus an escalating cascade of mPTP
opening, ROS production and injury so accounting for cardioprotection
[1,125].
4. Succinate stimulates ROS production following mPTP opening
As noted above, increased superoxide production can occur as a con-
sequence of mPTP opening and this may lead to further mPTP opening
in adjacent mitochondria [6,7]. Thus an alternative explanation for the
decreased ROS production caused by DMM treatment of both isolated
cardiomyocytes subject to simulated IR and in the in vivo ischemic re-
perfused hearts [23] would be that succinate enhances ROS production
after, rather than before, mPTP opening. In Fig. 5 we demonstrate that
this is the case. Isolated heart mitochondria were energised with gluta-
mate+malate in the presence (GMS) or absence (GM) of succinate and
continuous measurements made of light scattering (LS), mitochondrial
membrane potential (Δψ), extramitochondrial [Ca2+] and productionFig. 5. The [Ca2+]-sensitivity ofmPTP opening in isolatedheartmitochondria is reduced by succi
effects of sequential additions of Ca2+ (100 μmol/L) on isolated rat heart mitochondria incubat
(GMS) onmPTP opening and ROSproduction. Opening of themPTPwas detected as a loss ofΔψ
a decrease in LS while ROS production wasmonitored using Amplex Red in a parallel experimen
mean rates of ROSproduction (±SEMof 6 differentmitochondrial preparations) before Ca2+ ad
of the references to colour in this ﬁgure legend, the reader is referred to the web version of thiof hydrogen peroxide (rapidly formed from superoxide by SOD) as de-
scribed previously [7]. As noted by others [126–128], hydrogen perox-
ide production before Ca2+ addition was greatly enhanced by
succinate and this has been shown to involve superoxide production
at both Complex I and SDH. Sequential additions of 100 μM Ca2+ were
rapidly taken up by the mitochondria with a progressive reduction in
both Δψ and the rate of hydrogen peroxide production until the mPTP
opened (rapid and total loss of Δψ, release of accumulated Ca2+ and a
large LS decrease). Hydrogen peroxide production then increased once
more, conﬁrming the increased superoxide production that occurs
after mPTP opening. This may reﬂect the loss of cytochrome c and
NADPH from the mitochondria, both of which are important for ROS
scavenging [6,22]. Importantly, even after mPTP opening, rates of hy-
drogen peroxide production were considerably greater when succinate
was present than in its absence as shown in Fig. 5B. Very recent data
from Weiss's laboratory have also conﬁrmed that succinate increases
ROS production in heart mitochondria following mPTP opening [129].
This ROS was shown to be produced primarily at Complex II but might
also involve Complex III if this were damaged during ischemia [130].
Another important aspect of the data we present in Fig. 5A is that
many more additions of Ca2+ were required to induce mPTP opening
in the presence of succinate than its absence, despite succinate inducing
much higher rates of hydrogen peroxide production. These data are in
agreement with those obtained by others using skeletal muscle mito-
chondria [131] and suggest that succinate oxidation may actuallynate despite greater ROS production both before and after pore opening. Panel A shows the
ed with 5 mmol/L L-glutamate +2 mmol/L L-malate (GM) or GM plus 5 mmol/L succinate
(Rhd-123 ﬂuorescence increase) or accumulated Ca2+ (Fura-FFﬂuorescence increase) and
t on the samemitochondria. Further details may be found elsewhere [7]. Panel B presents
dition, after thepenultimate Ca2+ addition and following pore opening. (For interpretation
s article.)
Fig. 6. The extent of HK2 dissociation from mitochondria during ischemia is strongly
correlated with infarct size following reperfusion. HK activity was measured in
mitochondria isolated after 30 min ischemia and the infarct size after 2 h reperfusion.
The changes in HK activity was conﬁrmed to be due exclusively to HK2 dissociation by
Western blotting. The pre-treatments used to modify HK2 binding at the end of
ischemia were: Control (CP), ischemic preconditioned (IP) and perfusion with acetate
(Ac), high [Ca2+] (CaC) or high glucose (HG)with or without IP. Data are taken from [22].
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casts further doubt on the proposal of Chouchani et al. [23] that succi-
nate induced ROS production is a critical mediator of IR injury but is
supportive of earlier studies in which succinate was found to be
cardioprotective [92].
5. Alternative triggers for mPTP opening early in reperfusion
Our review of the available evidence leads us to conclude that it is
unlikely that an increase in matrix superoxide production at Complex
I, driven by REF from succinate, is the critical trigger for mPTP opening
in the initial phase of reperfusion. Rather, we suggest that the majority
of ROS are produced later in reperfusion and that this occurs as a conse-
quence of mPTP opening. This helps to drive a progressive cascade of
damage to the cardiomyocytes, including further mPTP opening and
ROS production as well as damage to proteins involved in ionic homeo-
stasis and calcium handling [132]. The result is an expanding area of ne-
crotic cell death that forms the infarct. If this conclusion is correct then
there must be other factors that trigger the initial mPTP opening and
that can be attenuated by cardioprotective protocols such as IP.We con-
sider some of these below.
5.1. The role of Ca2+
It is well established that calcium acts as an essential trigger for
mPTP opening and that many other factors that enhance pore opening
do so by increasing its sensitivity to [Ca2+] [1,12]. Increases in matrix
[Ca2+] have been demonstrated previously in both cardiac myocytes
[133] and perfused hearts [134] subject to ischemia and reperfusion.
We have recently conﬁrmed that increases in mitochondrial [Ca2+]
can be detected in the Langendorff-perfused heart after 30min ischemia
and 90 s of reperfusion [7]. It seems probable that this increase inmatrix
[Ca2+] is important formPTP opening since hearts of micewith an adult
cardiomyocyte-speciﬁc deletion of themitochondrial calcium uniporter
(MCU) were shown to exhibit reduced IR injury [135,136]. These data
conﬁrmed earlier reports that the MCU inhibitors ruthenium red and
Ru360 are cardioprotective [137,138]. Furthermore, mice with heart-
speciﬁc deletion of the mitochondrial Na+/Ca2+ exchanger (NCLX),
which is responsible formost Ca2+ efﬂux from thematrix of heartmito-
chondria, experienced substantial mitochondrial Ca2+ overload. This
was accompanied by increased generation of superoxide and necrotic
cell death in the heart and led to death of the mice within a few days.
However, the mice survived considerably longer if mitochondrial per-
meability transition pore activation was attenuated by additional
knockout of Cyp-D. Conversely, overexpression of NCLX in the mouse
heart enhanced mitochondrial Ca2+ efﬂux, prevented opening of the
mPTP and protected against ischemia-induced cardiomyocyte necrosis
and heart failure [139].
These data all conﬁrm the importance of increased matrix [Ca2+] in
triggering themPTP opening that leads to increasedROS production and
damage to the heart. However, we found no evidence that the
cardioprotection afforded by IP was accompanied by any attenuation
of this early rise in matrix [Ca2+], although IP did prevent the calcium
overload that occurred later in reperfusion [7]. We conﬁrmed that this
later calcium overload was secondary to mPTP opening by demonstrat-
ing that it was prevented by pre-treatment of the hearts with CsA, a
well-established mPTP inhibitor [7]. Others have come to a similar con-
clusion using an isolated myocyte model of IR [140]. It seems likely that
the calcium overload induced by the initial phase of mPTP openingmay
act in conjunction with the parallel increases in ROS to cause additional
mPTP opening in adjacent “unopened”mitochondria. This maymediate
a progressive cascade of further ROS production andmPTP opening that
will lead to a spreading area of necrotic cell death to form the infarct as
discussed above. Indeed, waves of [Ca2+] and ROS that precede mPTP
opening have been observed by confocal microscopy in the intact con-
traction-inhibited heart subject to hypoxia and re-oxygenation [141].Overall, we conclude that, although IP attenuated the secondary cal-
cium overload that follows mPTP opening, consistent with its ability to
inhibit mPTP opening [7,52,90,91], its inability to prevent the increase
in matrix [Ca2+] that occurs in the ﬁrst 90 s of reperfusion [7] implies
that another factor must play a critical role in regulating this ﬁrst
phase of mPTP opening. One possible candidate is mitochondria-
bound hexokinase 2 (HK2) whose extent of dissociation from mito-
chondria during ischemia correlates with infarct size and is prevented
by IP [27–29].
5.2. The role of mitochondria-bound hexokinase 2
It has been known formany years that both hexokinase 1 (HK1) and
hexokinase 2 (HK2) can bind to mitochondria and that such binding
may play an important role in the regulation of hexokinase activity
and thus of glucose metabolism [27,142,143]. However, more recently
evidence has emerged that binding of these enzymes to the outer mito-
chondrial membrane (OMM) may also decrease apoptosis mediated by
members of the Bcl2 family and antagonise mPTP opening [28]. Cardiac
myocytes express both HK1 and HK2 and both bind to the OMM
through an N-terminal hydrophobic domain but a signiﬁcant propor-
tion of HK2 is present in the cytosol [144,145]. The extent of HK2 bind-
ing to mitochondria depends on the prevailing metabolic conditions
with high concentrations of glucose-6-phosphate (G-6-P) favouring
HK2 dissociation [143,146]. Zuurbier and colleagues demonstrated a
progressive loss of bound mitochondria-bound HK2 during ischemia
of theheart [147] andwe conﬁrmed this, showing substantial loss ofmi-
tochondrial HK2, but not HK1, after 30 min global ischemia [148]. This
was associated with a loss of cytochrome c frommitochondria suggest-
ing enhanced permeability of the OMM. Furthermore, IP prevented both
the dissociation of HK2 and the loss of cytochrome c [22] and also de-
creased the calcium sensitivity of mPTP by isolated mitochondria [16].
Bymanipulating themetabolism of the perfused heart prior to ischemia
we were able to demonstrate [22] that there was a very strong inverse
correlation between the amount of HK2 remaining bound to mitochon-
dria at the end of ischemia and the infarct size after 120min of reperfu-
sion as shown in Fig. 6.
We have also shown that the increased susceptibility to IR of hearts
from high fat fed mice is associated with less mitochondrial bound HK2
[149] while others have demonstrated that hearts from HK2+/− mice
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such HK2 binding to mitochondria behaves in a manner that would be
expected of a key factor involved in determining the extent of mPTP
opening and IR injury. Thus, HK2 dissociation frommitochondria during
ischemiawill enhance cytochrome c release and predispose themPTP to
open early in reperfusion under conditions of increased matrix [Ca2+].
By preventing this HK2 dissociation from mitochondria during ische-
mia, IP prevents both cytochrome c loss andmPTP sensitisation thus ac-
counting, at least in part, for its cardioprotective effect. Very recent data
from Zuurbier's laboratory have provided further evidence in support of
this hypothesis. Rat hearts were perfused with low concentrations
(200 nM) of a membrane permeable peptide (TAT-HKII) that dissoci-
ates bound HK2 from mitochondria and which was without signiﬁcant
effect on normoxic hearts. However, after 15min ischemia,when reper-
fusion of control hearts caused only reversible injury (impaired hemo-
dynamic function), the presence of the TAT-HKII peptide caused
irreversible injury (lactate dehydrogenase release) [151].
Possible mechanisms by which IP may attenuate HK2 dissociation
from mitochondria during ischemia have been comprehensively
reviewed elsewhere [28] and are only brieﬂy summarised here. Attenu-
ation of the ischemia-induced increase in [G-6-P] and decrease intracel-
lular pH are critical, and reﬂect decreased glycogen levels prior to
ischemia [152–154]. Additional signalling pathways have also been pro-
posed including translocation of PKCε to themitochondriawhere itmay
phosphorylate VDAC1 to increase HK2 binding [155], althoughwewere
not able to conﬁrm this [16]. GSK3β and Akt have also been implicated
in IP [156,157]. Indeed, it has been proposed that the mechanisms of
many cardioprotective regimes converge to phosphorylate and inhibit
GSK3βwhose activity promotes mPTP opening [158,159]. Interestingly,
Akt has also been reported to phosphorylate Thr473 of HK2 directly with
the result that its binding to mitochondria in cardiomycoytes is en-
hanced while its sensitivity to dissociation by increased concentrations
of G-6-P is reduced [160,161]. However, others have reported that nei-
ther Akt stimulation with insulin nor genetic ablation of VDAC isoforms
1 and 3 affect cell death induction by HK2 dissociation [144]. Further-
more, insulin, a potent activator of the Akt pathway, is not
cardioprotective unless added during reperfusion [158]. Indeed, we
found that pre-ischemic treatment of hearts with insulin in place of
the IP protocol caused Akt and GSK3β phosphorylation to increase sev-
eral-fold yet no cardioprotection was observed [16] while others have
reported that such treatment may even suppress cardioprotection by
IP [162]. Nor were we able to detect signiﬁcant IP-mediated changes
in phosphorylation of any mitochondrial proteins (including VDAC
and HK2) [16]. Whatever the exact mechanisms(s) underlying the
regulation of HK2 binding to mitochondria, the very strong inverse
correlation between the extent of its binding at the end of ischemia
with the extent of damage (infarct size) following reperfusion (Fig.
6) suggests that it may play a key role in cardioprotection. An attrac-
tive feature of this proposal is that it provides a plausible explanation
of how, by converging on HK2 binding to mitochondria, a diverse
range of known cardioprotective protocols with distinct signalling
pathways can inhibit mPTP opening on reperfusion and so reduce
IR injury.
5.3. The role of mitochondrial contact sites and cristae morphology
The mechanism(s) that link(s) HK2 binding to mPTP opening re-
main uncertain, but an attractive hypothesis for which there is increas-
ing evidence is that HK2 bindingmodulates the interaction between the
inner mitochondrial membrane (IMM) and the OMM. Dissociation of
HK2 is proposed to alter the mitochondrial morphology and cristae
structure in such away as to increase OMMpermeability to cytochrome
c and sensitise mPTP opening to matrix [Ca2+] [28]. The presence of
“contact sites” between the IMM and OMM,where the twomembranes
interact closely, was ﬁrst revealed by freeze-fracture of mitochondria
and were shown to be dynamic structures which are affected by themetabolic status of mitochondria [163,164]. Several proteins have
been implicated in their formation including VDAC, ANT and, when
present, HK1, HK2 and creatine kinase (CK) [164,165]. Originally
thought to function primarily to enhance the transfer of ATP from the
matrix to the cytosol [163], contact sites were subsequently implicated
in the regulation of OMM permeability and mPTP opening [166]. We
presented evidence that destabilisation of contact sites may facilitate
opening of cristae junctions and thus access of cytochrome c within
the cristae to the permeation pathways in the OMM, and also increase
the sensitivity of themPTP towards [Ca2+] [167]. HK2 binding stabilises
contact sites [168,169] and thus it would be predicted that the loss of
HK2 during ischemia might lead to contact site breakage. In the per-
fused heart, there is good evidence that this is the case since operation
of the creatine phosphate (CrP) shuttle, which involves the interaction
of the ANT, CK and VDAC at contact sites, is impaired following ischemia
[170] but less so following IP [22,171]. Furthermore, using a variety of
preconditioning stimuli to modify mitochondrial HK2 binding at the
end of ischemia we conﬁrmed that maintenance of contact sites during
ischemia, as reﬂected in the recovery of CrP and hemodynamic function
on reperfusion, was greatest in hearts with the highest mitochondrial
HK2 binding [22]. The importance of contact sites in protecting mito-
chondria from mPTP opening is also consistent with the observation
that knockout of CK, whose presence stabilises contact sites [172],
makes hearts more sensitive to IR injury [173]. In addition, liver mito-
chondria from mice genetically modiﬁed to express mitochondrial CK
(which is normally absent in liver) demonstrated a 3-fold increase in
the number of contact sites as observed by EM [172], andweremore re-
sistant to mPTP opening by calcium [174].
Bcl-2 family members may also associate with the OMM at contact
sites, possibly binding to VDAC [142,175–177]. These proteins can inﬂu-
ence both OMM permeability and mPTP activity (see [178–180]) and
Bcl-xL has been shown to be lost from heart mitochondria during ische-
mia, perhaps leading to unmasking of pro-apoptotic members of the
Bcl-2 family such as Bax and Bak that are already in the OMM [22]. Fur-
thermore, adenovirus-mediated Bcl-xL gene transfer has been reported
to protect hearts from IR injury [181] while hearts from mice in which
both Bax and Bak have been knocked out are also protected from IR
[182]. The activity of members of the Bcl-2 family can also be regulat-
ed by phosphorylation, as well as by proteolysis and translocation
(see [178–180]) and this may provide yet further mechanisms by
which preconditioning can attenuate OMM permeabilisation and
mPTP opening in conjunction with its enhancement of HK2 binding.
So too may the HK2-regulated oligomerisation of VDAC1 in the OMM
that has recently been proposed as a pathway for cytochrome c re-
lease in apoptosis [176,183]. Indeed, inhibitors of this process have
been developed that prevent selenite-induced apoptosis and the as-
sociated cytochrome c release, ROS formation, mitochondrial depo-
larization and calcium overload [184]. Signiﬁcantly this is
accompanied by prevention of HK dissociation from the mitochon-
dria and the authors propose that HK binding to VDAC1 prevents
its oligomerization. This provides another plausible explanation for
the relationship between mitochondrial HK binding and resistance
to apoptosis and mPTP opening.
5.4. The role of mitochondrial ﬁssion
Theremay also be a link between contact site stability, mitochondri-
al cristaemorphology andmitochondrialﬁssion [28]. Thus the release of
cytochrome c from the intermembrane space during apoptosis, which is
associatedwithmitochondrialﬁssion, involves changes inmitochondri-
al cristae morphology allowing the cytochrome c within the cristae to
gain access to the permeabilised OMM [180]. A key player in mitochon-
drial ﬁssion is the GTPase Dynamin-related protein 1(Drp1) [180,185,
185] which must be recruited to the OMM. Importantly, mitochondria
have been reported to undergo ﬁssion during ischemia of the perfused
heart and this might be a critical factor in inducing the observed
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the inhibitor Mdiv-1 [186–189] or transgenic expression of a dominant
negative form of Drp1 [190] was found to reduce infarct size following
IR. This was accompanied by preserved mitochondrial morphology, re-
duced mitochondrial ROS production and improved hemodynamic
function [189]. Another attractive feature of Drp1 is the complex regula-
tion of its translocation to and from mitochondria. Drp1 can be phos-
phorylated on either Ser616 or Ser637 by different protein kinases but
only the former promotes its translocation tomitochondria [189]. Inter-
estingly, the kinase responsible for Ser616 phosphorylation is PKCδ
which becomes active during ischemia [191]. Similarly, Ser637 isFig. 7. Proposed sequence of events in ischemia and reperfusion that lead tomPTP opening and
those presented previously [7,28].phosphorylated by PKA that is active after pre-conditioning or TP [21]
and promotes Drp1 dissociation from mitochondria. Thus, in a similar
manner to HK2, it would seem possible that Drp1 can also act as a com-
mon locus that links different responses to IR and mitochondrial fate.
Furthermore, Drp1 has been shown to associatewithmitochondria dur-
ing ischemia [187,192,193] and to facilitate calcium ﬂux and cristae re-
modeling during apoptosis [194] in anMid49/51-dependent and OPA1-
independent fashion [195]. It is possible that the opposite translocation
of Drp1 and HK2 during ischemia and cardioprotective regimens may
reﬂect a shared but competing binding region on the OMM. Indeed,
very recent studies in neonatal cardiac myocytes have demonstrated areperfusion injury and their attenuation by IP. This scheme is a slightlymodiﬁed version of
11T.N. Andrienko et al. / Journal of Molecular and Cellular Cardiology 110 (2017) 1–14reciprocal interaction between Drp1 and HK2 binding to mitochondria
[196]. Treatment of the myocytes with 100 μM palmitic acid for 2 h en-
hanced Drp1 binding tomitochondria while reducing HK2 binding, and
this was associated with increased mPTP opening and ROS and [Ca2+]
levels. Treatment with 2-deoxy-glucose also reduced mitochondrial
HK2 binding while promoting Drp1 translocation to mitochondria. Fur-
thermore, knockdown of Drp1 using siRNA prevented the loss of HK2
induced by palmitic acid as did increasing Drp1 phosphorylation by
Akt activationwhich also prevented themPTP opening and the associat-
ed increases in [ROS] and [Ca2+].
6. Conclusions
Our own data together with a critical analysis of the published data
of others lead us to conclude that it is unlikely that signiﬁcant superox-
ide production in themitochondrial matrix, driven by succinate-fuelled
REF, occurs in the early phase of reperfusion (i.e. the ﬁrst 2 min). Hence
we suggest that thismechanism is unlikely to be a criticalmediator of IR
injury. Rather we would argue that the evidence favours the initial
phase of mPTP opening being triggered by factors other than matrix
ROS while the large increase in ROS seen later in reperfusion occurs as
a consequence of mPTP opening. This secondary rise in ROS may play
an important role in causing an escalating cascade of mPTP opening
that leads to a spreading wave of necrotic cell death and the formation
of the infarct. An important stimulus for the ﬁrst phase ofmPTP opening
is likely to be the observed increase inmitochondrialmatrix [Ca2+] dur-
ing ischemia and early reperfusion. However, it cannot be the only trig-
ger because the increase in [Ca2+] is not attenuated by IP, yet IP inhibits
mPTP opening and provides cardioprotection. A promising additional
candidate for regulating the initial phase of mPTP opening is mitochon-
drial bound HK2which dissociates from themitochondria during ische-
mia, but not following IP. Dissociation of bound HK2 is associated with
an increase loss of cytochrome c from themitochondria during ischemia
and an enhanced sensitivity tomPTP opening. This provides an explana-
tion of the very close correlation between the extent of HK2 loss from
mitochondria during ischemia and the extent of injury (infarct size)
on subsequent reperfusion. The mechanisms linking HK2 dissociation
to OMMpermeabilisation, cytochrome c release andmPTP sensitisation
remain to be fully established but the available evidence implicates sev-
eral related processes: the stability of contact sites between the inner
and outer membranes, cristaemorphology and VDAC1 oligomerisation.
This is illustrated diagrammatically in Fig. 7. The involvement of these
interacting processes provides potential loci for the established effects
on IR injury of mitochondrial ﬁssion proteins such as Drp1 (knockout/
inhibition is cardioprotective), members of the Bcl-2 family such as
Bcl-xL, whose overexpression is cardioprotective, and Bax and Bak
whose knockout is cardioprotective, and proteins enhancing contact
site formation such as HK2 and mitochondrial CK whose knockout en-
hances damage. However, further work will be required to test this hy-
pothesis and elucidate the underlying mechanisms that link these
processes to the regulation of mPTP opening and the development of
IR injury.
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